Design of a gastroretentive mucoadhesive dosage form of furosemide for controlled release  by Darandale, Sharad S. & Vavia, Pradeep R.
Chinese Pharmaceutical AssociationInstitute of Materia Medica, Chinese Academy of Medical Sciences
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2012;2(5):509–5172211-3835 & 2012 In
hosting by Elsevier B
http://dx.doi.org/10.1
nCorresponding au
E-mail address: p
Peer review under rwww.elsevier.com/locate/apsb
www.sciencedirect.comORIGINAL ARTICLE
Design of a gastroretentive mucoadhesive dosage form
of furosemide for controlled releaseSharad S. Darandale, Pradeep R. VavianDepartment of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai 400019, India
Received 24 November 2011; revised 20 March 2012; accepted 29 March 2012KEY WORDS
Gastroretentive dosage
form;
Controlled release;
Furosemide;
Bioadhesion;
Bilayer ﬁlm;
Hydroxypropyl
b-cyclodextrin;
Carbopolstitute of Materia M
.V. All rights rese
016/j.apsb.2012.05
thor. Tel.: þ91 22
r.vavia@ictmumb
esponsibility of InstAbstract The aim of the present study was to develop and characterize a gastroretentive dosage
form suitable for controlled drug release. It consists of a drug loaded polymeric ﬁlm made up of a
bilayer of immediate (IR) and controlled release (CR) layers folded into a hard gelatin capsule.
Gastroretention results from unfolding and swelling of the ﬁlm and its bioadhesion to the gastric
mucosa. Furosemide, a drug with a narrow absorption window, was selected as the model drug.
Inclusion of hydroxypropyl b-cyclodextrin in both layers and Carbopols 971P NF in the CR layer
of the bilayer ﬁlm resulted in optimum drug release, bioadhesion and mechanical properties. The
ﬁlm with zig-zag folding in the capsule was shown to unfold and swell under acidic conditions and
provide IR of drug over 1 h and CR for up to 12 h in acidic medium. X-ray diffraction, differential
scanning calorimetry and scanning electron microscopy revealed uniform dispersion of furosemide
in the polymeric matrices. The results indicate the dosage form is gastroretentive and can provide
controlled release of drugs with narrow therapeutic windows.
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The development of controlled release formulations has had a
tremendous impact on the drug delivery ﬁeld particularly for
drugs with a narrow absorption window. However, typical
controlled release formulations are limited by insufﬁcient
retention in the stomach. To extend the residence time of
dosage forms in the stomach, a number of strategies have been
developed1–4, including (a) reducing the density to promote
ﬂoating in the gastric contents, (b) increasing the density
to promote retention in the lower part of the stomach,
(c) introducing mucoadhesive properties and (d) producing a
formulation that swells or unfolds in the stomach to hinder its
escape through the pyloric sphincter. Each of these
approaches has its advantages and disadvantages.
An alternative strategy is to combine bioadhesion with the
ability to expand by unfolding and swelling. This paper describes
the design of a formulation incorporating a drug loaded
polymeric ﬁlm folded in a hard gelatin capsule. After ingestion,
the capsule dissolves and releases the ﬁlm which then unfolds in
the stomach and swells to a larger dimension resulting in its
increased retention. The concept of a gastroretentive drug loaded
polymeric ﬁlms has been previously reported and the effects of
shape, folding pattern and polymer characteristics on perfor-
mance of gastroretention has been studied1.
Although this type of dosage form has various advantages such
as the convenience of a hard gelatin capsule and the ability to
modify drug release through using a multilayer design, there
remain a number of issues. These include the difﬁculty in
formulating a drug loaded polymeric ﬁlm and the selection of a
polymer with the desired ability to unfold and expand in the
stomach. This paper focuses on practical aspects of designing such
a dosage form and the difﬁculties encountered in its development.
Furosemide (4-chloro-2-furfurylamino-5-sulphamoyl benzoic
acid) is a loop diuretic widely used in the treatment of congestive
heart failure and edema. It works by inhibiting the Naþ/Kþ/
2Cl transporter in the ascending limb of the loop of Henle5.
Furosemide is a Biopharmaceutical Classiﬁcation System (BCS)
class IV drug with poor aqueous solubility and permeability. It is
mainly absorbed in the upper gastrointestinal tract and has a
short half life of less than 2 h. The conventional dosage form
shows erratic absorption which results in poor bioavailability
(30–60%) and the requirement for dosing 3–4 times/day6. In
addition, the peak diuretic effect results in signiﬁcant adverse
effects in some geriatric patients. On this basis, a controlled
release formulation of furosemide is very desirable.
Generally, a controlled release formulation is designed to
provide immediate release (IR) to achieve the therapeutic drug
concentration in a short period of time and controlled release
(CR) to maintain the concentration for the desired period of time.
The dose of furosemide to be incorporated in the developed
formulation was decided on the basis of the in vitro release pattern
of the marketed formulation, Lasix Retards 60 mg. It was found
that the marketed formulation showed the desired controlled
release in pH 6.8 buffer but slower release at lower pH
(Supplementary Fig. 1). At pH 6.8, about 30% of the drug was
released in the ﬁrst hour followed by release of the remaining drug
over the subsequent 12 h. By considering biopharmaceutical
parameters including oral bioavailability, half life and plasma
steady state concentration7, it was decided to design a formulation
incorporating 30% of the total furosemide dose in a polymeric
ﬁlm for IR and the remainder in a mucoadhesive ﬁlm folded andinserted in a capsule for CR. The aim was to design a dosage form
providing optimal drug release for maximum absorption.2. Materials and methods
2.1. Materials
Furosemide was obtained from Ipca Labs (Mumbai, India).
Polyvinyl alcohol (Gohnesols), hydroxypropyl methylcellulose
(Methocels E4M, HPMC E4M), poly(ethyl acrylate-
co-methyl methacrylate-co-trimethylammonioethyl methacry-
late chloride) (Eudragits RLPO) and acrylic acid polymer
(Carbopols 971P NF) for preparation of polymer ﬁlms were
provided by Nippon Gohsei (Japan), Colorcon (India),
Degussa-Evonik (Germany) and Noveon (India) respectively.
Polyethylene glycol 400 (PEG 400, Lutrols E400) from Merck
(India) was used as a plasticizer. PEG-40 hydrogenated castor
oil (Cremophores RH 40), 2-pyrrolidinone (Soluphors P) and
hydroxypropyl b-cyclodextrin (HPBCD, KleptosesHP) for use
as solubilizers were supplied by BASF Ltd. (Germany), Color-
con (India) and Signet Chemical Corporation (India) respec-
tively. All other reagents and chemicals were of analytical
reagent grade and used as received.2.2. Preparation of ﬁlms
Films with single and double layers were prepared by the
solvent casting method on a Mathis lab dryer and lab coater
(Mathis AG, Switzerland) using a knife over the roll assembly.
Preparation of the solutions used to make single ﬁlms and the
method of making the bilayer ﬁlm are as follows.2.2.1. Solution A (controlled release (CR) layer)
A polymeric dispersion was prepared by dissolving HPMC
E4M, Eudragits RLPO, Carbopols 971P NF (5:0.95:0.05) in
isopropanol:water (3:1). A furosemide solution was prepared
containing furosemide:Soluphors P:Cremophores RH 40 in
the ratio 1:1.75:1.75. The furosemide solution was mixed with
the polymeric dispersion (1:1) followed by addition of
HPBCD (1.5 M) with vigorous stirring to give solution A.2.2.2. Solution B (immediate release (IR) layer)
Polyvinyl alcohol (15% w/w) was dissolved in distilled water
to which PEG 400 (5%, w/w) was added as plasticizer.
Furosemide was dissolved in 0.05 M NaOH solution and the
solution mixed with the polymer solution (1:1) followed by
addition of HPBCD (1.5 M) with vigorous stirring to give
solution B.2.2.3. Bilayer ﬁlm
First solution A was cast on the release liner and allowed to
dry at 40 1C for at least 90 min. Then solution B was cast over
the formed controlled release layer and allowed to dry for
60 min at 40 1C followed by 30 min at 60 1C. On removal for
the release liner, the ﬁlms were checked for possible imperfec-
tions before being cut into 4 cm 2 cm rectangles and used to
ﬁll hard gelatin size 00 capsules by zigzag folding.
Figure 1 Folding patterns of ﬁlm in hard gelatine capsule for (A) Case I and (B) Case II.
Table 1 Composition of formulations containing differ-
ent HPMC E4M concentrations in the CR layer.
Ingredient Formulation
F1 F2 F3
IR layer
Drug 1 1 1
Soluphors P 1.75 1.75 1.75
Cremophores RH 40 1.75 1.75 1.75
PEG 400 0.75 0.75 0.75
Polyvinyl alcohol 15 15 15
Water 100 100 100
CR layer
Drug 1 1 1
Soluphors P 1.75 1.75 1.75
Cremophores RH 40 1.75 1.75 1.75
Eudragits RLPO 5 5 5
HPMC E4M 0.5 1 1.5
Isopropanol:water (3:1) 100 100 100
All values are % w/w.
Table 2 Composition of formulations containing differ-
ent HPBCD concentrations in both IR and CR layers.
Ingredient Formulation
F2 F4 F5 F6
IR layer
Drug 1 1 1 1
HPBCD 0 0.5 1 1.5
PEG 400 0.75 0.75 0.75 0.75
Ployvinyl alcohol 15 15 15 15
Water 100 100 100 100
CR layer
Drug 1 1 1 1
HPBCD 0 0.5 1 1.5
Soluphors P 1.75 1.75 1.75 1.75
Cremophors RH 40 1.75 1.75 1.75 1.75
Eudragits RLPO 5 5 5 5
HPMC E4M 1 1 1 1
Isopropanol:water (3:1) 100 100 100 100
All values are % w/w except that HPBCD is in molar
proportion to drug.
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The drug loaded polymeric ﬁlm was optimized for folding
behavior, drug release, mucoadhesion and integrity as
described below.
2.3.1. In vitro unfolding study
Two methods of ﬁlm folding were compared for their ability
to unfold. In case I, the two layers remained separated; the CR
layer was folded in a zig-zag manner and the IR layer rolled
over the CR layer (Fig. 1A) before insertion into the capsule.
In case II, the bilayer ﬁlm was prepared and folded in a zig-zag
manner (Fig. 1B) before insertion into the capsule. Eight
capsules of each type were prepared and subjected to an
in vitro dissolution study in 900 mL aqueous hydrochloric acid
pH 1.2 at 37.570.5 1C using the USP XXIII Apparatus 1
(basket) at 50 rpm. Baskets were removed after 5, 15, 30, 60,
120, 240, 480 and 720 min and the ﬁlms examined for their
unfolding behavior.
2.3.2. Effect of HPMC E4M concentration in the CR layer
Different formulations of the CR layer were prepared by
varying the concentration of HPMC E4M whilst maintainingthe composition of the IR layer as shown in Table 1. In vitro
drug release of the prepared formulations in 900 mL pH 6.8
phosphate buffer, aqueous hydrochloric acid pH 1.2 and pH
4.5 acetate buffer was determined as described in Section 2.3.1.
Samples were removed at 0, 1, 2, 4, 8 and 12 h and furosemide
content analyzed by UV spectrophotometry at 274 nm. Stan-
dard curves in media at pH 1.2, 4.5 and 6.8 were y¼0.0586xþ
0.0039 (R2¼0.9999), y¼0.0641xþ0.0101 (R2¼0.9996), y¼
0.634xþ0.0032 (R2¼0.9996) and y¼0.0625xþ0.0178 (R2¼
0.9989), respectively. The UV spectra of placebo and drug
containing formulations were compared to show the assay was
free from interference from constituents in the formulations
(Supplementary Fig. 2).2.3.3. Effect of HPBCD concentration in both layers
To reduce the effect of pH on the formulation, HPBCD was
incorporated. Batch F2 from the study described in Section 2.3.2
was prepared by incorporating HPBCD in both layers (IR and
CR) with different drug:HPBCD molar ratios (Table 2). In vitro
drug release in aqueous hydrochloric acid pH 1.2 was tested at
37.570.5 1C and 50 rpm as described above.
Table 3 Composition of formulations containing differ-
ent Carbopols 971P NF: HPMC E4M ratios in the
CR layer.
Ingredient Formulation
F6 F7 F8 F9
IR layer
Drug 1 1 1 1
HPBCD 1.5 1.5 1.5 1.5
PEG 400 0.75 0.75 0.75 0.75
Ployvinyl alcohol 15 15 15 15
Water 100 100 100 100
CR layer
Drug 1 1 1 1
HPBCD 1.5 1.5 1.5 1.5
Soluphors P 1.75 1.75 1.75 1.75
Cremophors RH 40 1.75 1.75 1.75 1.75
Eudragits RLPO 5 5 5 5
HPMC E4M 1 0.75 0.9 0.95
Carbopol 971P NF 0 0.25 0.1 0.05
Isopropanol:water (3:1) 100 100 100 100
All values are % w/w except that HPBCD is in molar
proportion to drug.
Sharad S. Darandale, Pradeep R. Vavia5122.3.4. Effect of Carbopols 971P NF: HPMC E4M ratio in
the CR layer
To improve the integrity of the ﬁlm during in vitro dissolution,
Carbopols 971P NF was incorporated in the CR layer of the
formulation. The composition of the IR layer was the same for
each formulation whilst that of the CR layer contained
different proportions of Carbopols 971P NF and HPMC
E4M (Table 3). The prepared formulations were tested for
in vitro drug release, bioadhesion, swelling and mechanical
performance.
2.3.4.1. In vitro bioadhesion. Bioadhesion of the CR layer of
the ﬁlm to stomach mucosa was evaluated in triplicate using a
double beam physical balance as described previously8.
Brieﬂy, the stomach mucosa of Wistar rats was excised,
washed with Tyrode’s solution and tied tightly (mucosal side
upwards) using a thread to the end of a cylindrical Teﬂon
block. The cylinder was placed into a glass container which
was then ﬁlled with either aqueous hydrochloric acid pH 1.2
or pH 4.5 acetate buffer at 3771 1C until the ﬂuid just reached
the surface of the mucosal membrane. This was placed below
the left arm of the balance. The moist ﬁlm was then brought
into contact with a ﬁlm (CR layer downwards) attached to the
lower surface of another Teﬂon cylinder suspended from the
left arm of the balance by removing a 5 g weight from the right
pan of the balance. The balance was kept in this position for
3 min after which weights were added slowly to the right pan
until the ﬁlm separated from the mucosal surface. The excess
weight on the pan (total weight minus 5 g) is the bioadhesive
strength required to separate the ﬁlm from the mucosa. The
force of adhesion was calculated using the formula:
Force of adhesion ðNÞ ¼ ðBioadhesive strength=1000Þ  9:81
ð1Þ
2.3.4.2. In vitro residence time. The in vitro residence time
was determined in triplicate as described previously9. The CRside of a ﬁlm was applied to freshly prepared rat stomach
mucosa ﬁxed to a glass slide with cyanoacrylate glue and
suspended from a reciprocating motor. The slide was sus-
pended in a beaker ﬁlled with 800 mL aqueous hydrochloric
acid pH 1.2 or pH 4.5 acetate buffer and moved vertically in
and out of the medium by switching on the motor. The
experiment was continued until the ﬁlm detached or eroded
from the mucosa.
2.3.4.3. Swelling behavior. Swelling of ﬁlms was examined in
triplicate in simulated gastric ﬂuid (pH 1.2) and pH 4.5 acetate
buffer according to the following procedure10. After recording
the initial weight of a ﬁlm (W1), it was immersed in medium
maintained at 3771 1C for 360 min and then weighed again
(W2). The swelling ratio was determined as (W2W1)/W1.
2.3.4.4. Mechanical performance. Mechanical properties of
ﬁlms free of physical defects were determined in triplicate
using a universal testing machine (UTM, LLOYD) as pre-
viously described11,12. Rectangular samples of ﬁlm (30 mm 5
mm) were subjected to analysis based on ASTM D-882. The
ﬁlms were carefully placed between the two vertical grips of
the tester and the movable grip then driven upward at 5 mm/
min until the ﬁlm ruptured. From the recorded load-extension
proﬁle, the tensile strength, percent elongation at break and
Young’s modulus were calculated.2.4. Characterization of optimized formulation
2.4.1. In vitro drug release
In vitro dissolution of optimized formulation F9 was studied in
media of different pH using the procedure described in Section
2.3.2. Dissolution of the marketed formulation, Lasix Retards
60 mg, was also determined in aqueous hydrochloric acid pH 1.2
for comparison. In vitro release proﬁles were ﬁtted to different
kinetic models including zero order, ﬁrst order, Korsmeyer–
Peppas model, Higuchi model and Hixson–Crowell model and
the correlation coefﬁcients of the ﬁts compared.2.4.2. Scanning electron microscopy (SEM)
Morphological characteristics (deformities, drug crystals and
cracks) of the IR layer, CR layer and bilayer ﬁlm of formula-
tion F9 were studied using a Jeol Scanning Electron Microscope
(JSM-6380 LA) at an acceleration voltage of 10 kV.2.4.3. Differential scanning calorimetry (DSC)
The thermal behavior of furosemide, HPBCD, the IR layer,
CR layer and bilayer ﬁlm of formulation F9 was estimated in
terms of their melting endotherms using a Pyris 6 instrument
(Perkin Elmer) with 3 mg ﬁlm samples in standard aluminium
pans. The samples were heated from 30 1C to 250 1C at a
constant rate of 5 1C/min under nitrogen.2.4.4. X-ray diffraction (XRD)
XRD analysis was carried out to characterize the physical
structure (crystallinity, amorphousness, etc.) of furosemide,
HPBCD, the IR layer, CR layer and bilayer ﬁlm of formula-
tion F9 using a Rigaku Miniﬂex instrument (Japan) with ‘‘Ni-
ﬁltered’’ CuK radiation of wavelength l¼1.54060 A˚. The scan
was taken in the 2y range of 5–401 with a scanning speed and
step size of 11/mm and 0.011, respectively.
Figure 2 Unfolding behavior of Case II ﬁlm.
Figure 3 In vitro release of furosemide in pH 6.8 buffer as a function of (A) HPMC E4M concentration (% w/w) in the CR layer in
batches: F1, 1.5%; F2, 1%; F3, 0.5%. (B) In vitro release of furosemide from batch F2 in aqueous hydrochloric acid pH 1.2 and pH 4.5
and 6.8 buffers.
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3.1. Unfolding behavior
The unfolding behavior of the IR and CR ﬁlms placed separately
in case I capsules was not acceptable in that, although the IR layer
dissolved within 10 min and the CR layer swelled with time, the
CR layer failed to unfold (Supplementary Fig. 3). In contrast, the
behaviour of the bilayer ﬁlm in case II capsules was satisfactory in
that the CR layer swelled and the ﬁlm unfolded in an acceptable
manner (Fig. 2).
The problem of unfolding of a ﬁlm arises due to a reduction in
its resiliency to restore its original shape (its so-called mechanical
shape memory) after prolonged stress applied during its storage1.
Films made of polymeric material with prolonged shape memory
are therefore useful since they undergo less plastic deformation
and maintain their elasticity whilst folded. Such polymers have
glass transition temperatures close to ambient temperature. Inthe present formulation, the CR layer was prepared from
polymeric materials (Eudragits RLPO, HPMC E4M and
Carbopols 971P NF) with very high glass transition tempera-
tures. In contrast, the IR layer was prepared from polyvinyl
alcohol which has a glass transition temperature closer to
ambient temperature. In using a bilayer as in case II, the IR
layer helps to maintain the mechanical shape memory of the CR
layer resulting in a ﬁlm with the desired unfolding characteristics.
The CR layer failed to unfold after release from case I capsules
due to its low mechanical shape memory.
3.2. Optimization of formulation
3.2.1. Effect of HPMC E4M concentration in the CR layer
An increase in the HPMC E4M concentration in the CR layer
was found to retard drug release from the bilayer in pH 6.8
phosphate buffer (Fig. 3A). Batch F2 showed a better
controlled release proﬁle than batches F1 and F3 which
Figure 4 In vitro release of furosemide in aqueous hydrochloric
acid pH 1.2 as a function of HPBCD concentration (in molar
proportion to drug) in batches: F2, 0; F4, 0.5; F5, 1; F6, 1.5.
Figure 5 In vitro release of furosemide in aqueous hydrochloric
acid pH 1.2 as a function of Carbopols 971P NF: HPMC E4N
ratio (total concentration 1% w/w) in the CR layer in batches: F6,
0:1; F9, 0.05:0.95; F8, 0.1:0.9; F7, 0.25:0.75.
Figure 6 Effect of Carbopols 971P NF: HPMC E4N ratio (total
concentration 1% w/w) in the CR layer on in vitro bioadhesion of
the CR layer for batches: F6, 0:1; F9, 0.05:0.95; F8, 0.1:0.9; F7,
0.25:0.75.
Figure 7 Effect of Carbopols 971P NF: HPMC E4N ratio (total
concentration 1% w/w) in the CR layer on in vitro residence time
of the CR layer for batches: F6, 0:1; F9, 0.05:0.95; F8, 0.1:0.9; F7,
0.25:0.75.
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tion, HPMC swells and creates a viscous gel around the ﬁlm
which is resistant to water penetration. Dissolved drug is
released by diffusion through the viscous gel but, with an
increase in HPMC concentration, the thickness of the gel layer
increases and release of drug is retarded13.
Comparison of the release proﬁles of batch F2 in aqueous
hydrochloric acid pH 1.2 and pH 4.5 acetate buffer with that
in pH 6.8 phosphate buffer is shown in Fig. 3B. Given that
furosemide is practically insoluble at acidic pH, the slower
drug release with decreasing pH is to be expected.3.2.2. Effect of HPBCD concentration in both layers
An increase in the HPBCD concentration in both layers
resulted in a proportional increase in drug release (Fig. 4).
This is consistent with the reported increase in solubility of
furosemide in the presence of HPBCD14. HPBCD has high
water solubility and is extensively applied to increase perme-
ability and aqueous solubility of poorly soluble drugs15.3.2.3. Effect of Carbopols 971P NF: HPMC E4M ratio in
the CR layer
3.2.3.1. Drug release. The increase in Carbopols 971P NF:
HPMC E4M ratio in the CR layer (F6oF9oF8oF7)
(Table 3) led to a small but proportional decrease in drug
release (Fig. 5). In order to optimize the controlled release
proﬁle of furosemide, the integrity of the bilayer ﬁlm needs to
be maintained throughout the dissolution period. As stated in
Section 3.2.1, HPMC forms a viscous, swollen and non-
continuous gel on dissolution due to its high hydration index16
whereas Carbopol undergoes less swelling because less than
10% of the acrylic acid groups are ionized at lower pH
resulting in little stiffening by electrostatic charge repulsion.
This helps to maintain the integrity of the ﬁlm.
3.2.3.2. In vitro bioadhesion. The formulations containing
both Carbopol 971P NF and HPMC E4M (Batches F7, F8
and F9) showed greater in vitro mucoadhesion than the
formulation with no Carbopol (Batch F6) (Fig. 6). The reason
for the weaker mucoadhesion of batch F6 is because the
proton donating carboxylic groups in the acrylic acid polymer,
Carbopols 971P NF, form hydrogen bonds with the nega-
tively charged mucus gel leading to greater physical entangle-
ments17 and improved mucoadhesion. In addition, HPMC
E4M has more neutral cellulose groups and thus forms fewer
hydrogen bonds with glycoprotein mucin leading to weaker
adhesive forces18. Thus the high molecular weight, presence of
strong hydrogen bond forming groups (carboxylic acid),
anionic nature and sufﬁcient chain ﬂexibility all contribute
to the beneﬁt of including Carbopol 971P NF19.
Figure 8 Effect of Carbopols 971P NF: HPMC E4N ratio (total
concentration 1% w/w) in the CR layer on swelling behavior of
the CR layer for batches: F6, 0:1; F9, 0.05:0.95; F8, 0.1:0.9; F7,
0.25:0.75.
Figure 9 Effect of Carbopols 971P NF: HPMC E4N ratio (total
concentration 1% w/w) in the CR layer on mechanical perfor-
mance of the CR layer. (A) tensile strength; (B) Young’s modulus;
(C) deformation at break for batches F6, 0:1; F9, 0.05:0.95; F8,
0.1:0.9; F7, 0.25:0.75.
Figure 10 In vitro release of furosemide from batch F9 in buffers
of different pH.
Figure 11 Comparison of in vitro release of furosemide in
aqueous hydrochloric acid pH 1.2 from the marketed formulation,
Lasix Retards 60 mg, and batch F9.
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follows the same principle as in vitro bioadhesion, it is not
surprising that residence time for the four formulationsincreased to a small but proportional extent as the Carbopols
971P NF: HPMC E4M ratio increased (Fig. 7).
3.2.3.4. Swelling behavior. Generally, the swelling of poly-
mers results in enhancement of their mucoadhesion. Here it
was found that the swelling of ﬁlms decreased as the
Carbopols 971P NF: HPMC E4M ratio in the CR layer
increased (Fig. 8). However, the results contradict those of the
mucoadhesion study in that Carbopols 971P NF in the ﬁlm
leads to a reduction in swelling but enhanced mucoadhesion.
3.2.3.5. Mechanical performance. Films with increasing
Carbopols 971P NF: HPMC E4M ratio showed poorer
mechanical performance with batch F6 showing the highest
tensile strength (Fig. 9A), and Young’s modulus (Fig. 9B) and
the lowest deformation at break (Fig. 9C). The decrease in tensile
strength results from the lower glass transition temperature of
Carbopols 971P NF as compared to HPMC E4M.
As the optimum formulation should combine the best
combination of in vitro drug release, mucoadhesion and
mechanical performance, formulation F9 was selected as the
optimized formulation. The results of the study of mechanical
performance conﬁrm that formulation F9 has sufﬁcient
strength, ﬂexibility and elasticity.
Table 4 Correlation coefﬁcient (R2) and constant (K) of
different kinetic models of drug release for formulation F9
in aqueous hydrochloric acid pH 1.2.
Kinetic model Parameter Value
Zero order R2 0.6151
K0 8.852
First order R2 0.9335
K1 0.197
Krosmeyer–Peppas R2 0.999
KP 30.93
n 0.414
Higuchi R2 0.9862
KH 26.2
Hixon–Crowell R2 0.885
KHc 0.053
nRelease exponent.
Figure 12 Scanning electron microscopy of the bilayer ﬁlm.
Figure 13 X-ray diffraction patterns of furosemide, HPBCD and
the IR, CR and bilayer ﬁlms.
Figure 14 DSC thermograms of furosemide, HPBCD and the
IR, CR and bilayer ﬁlms.
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3.3.1. In vitro drug release
In vitro drug release from formulation F9 in media of different
pH follows a similar pattern (Fig. 10) with a small increase in
amount released with increasing pH from 1.2 to 6.8. Compar-
ison of the drug release pattern of formulation F9 with that
from the marketed formulation, Lasix Retards 60 mg
(Fig. 11), shows release was signiﬁcantly greater from F9
(89% versus 10% after 12 h). This is partly because of the
rapid release during the ﬁrst hour (about 30% drug release)
resulting from dissolution of the IR layer. As described earlier,
the mechanical properties of the IR layer facilitate unfolding
of the ﬁlm that then provides controlled drug release over the
subsequent period of 12 h.
Table 4 shows the correlation coefﬁcients of different
kinetic models for drug release from formulation F9 in
aqueous hydrochloric acid pH 1.2. The best ﬁt was to the
Korsmeyer–Peppas model (r2¼0.999) closely followed by theHiguchi model. The release exponent n of 0.414 indicates
release occurs by Fickian diffusion 20.
3.3.2. SEM
Both layers of the bilayer ﬁlm were macroscopically homo-
geneous and fairly transparent with no crystals on either
surface of the ﬁlm (Supplementary Fig. 4). The presence of
streaking may be due to high consistency of the dispersion or
to problems with the casting procedure. The lateral view of the
ﬁlm (Fig. 12) clearly shows the presence of both the IR and
CR layers.
3.3.3. XRD
The XRD pattern of furosemide displays crystallinity whereas
the diffractogram of HPBCD shows an amorphous pattern.
The diffractograms of the IR layer, CR layer and bilayer ﬁlm
(Fig. 13) show amorphous characteristics with drug crystal-
linity decreasing from 57.2% to 10.7% in the IR layer, to
8.77% in the CR layer and to 9.42% in the bilayer ﬁlm. These
changes indicate uniform molecular dispersion of furosemide
in the polymer matrices.
3.3.4. DSC
The DSC of furosemide exhibits a sharp exothermic peak at
220.8 1C corresponding to its melting point which is usually
Design of a gastroretentive mucoadhesive dosage form of furosemide for controlled release 517associated with decomposition of the drug. The peak did not
appear in the thermograms of any of the polymeric ﬁlms
(Fig. 14) again indicating that drug is uniformly entrapped in
the polymeric matrices.4. Conclusions
A gastroretentive dosage form for controlled release of furose-
mide, a drug with a narrow absorption window, has been
developed and characterized. It consists of a drug loaded poly-
meric ﬁlm with immediate (IR) and controlled release (CR) layers
folded inside a hard gelatin capsule. The optimized ﬁlm formula-
tion showed satisfactory controlled release, mucoadhesion and
integrity during the release period. The presence of Carbopols
971P NF in the CR layer and HPBCD in both layers was crucial
to provide good dissolution, bioadhesion and mechanical perfor-
mance of the ﬁlm. The ﬁlm with zig-zag folding undergoes
appropriate unfolding and expansion in acidic media which,
combined with good bioadhesion, indicates the gastroretentive
potential of the dosage form. The combination of these favorable
characteristics suggests the dosage form is worthy of further
development through its evaluation in in vivo studies.
Acknowledgments
The authors are grateful to the University Grant Commission
(UGC), Government of India and CSIR, India for ﬁnancial
assistance, and to the AICTE-NAFETIC for providing the
facilities to perform the experimental work.Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.apsb.2012.05.004.References
1. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable
gastroretentive dosage forms. J Control Release 2003;90:143–62.
2. Singh BN, Kim KH. Floating drug delivery systems: an approach
to oral controlled drug delivery via gastric retention. J Control
Release 2000;63:235–59.
3. Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug
Carrier Syst 1993;10:143–95.4. Srikanth MV, Rao NS, Sunil SA, Ram BJ, Kolapalli VR.
Statistical design and evaluation of a propranolol HCl gastric
ﬂoating tablet. Acta Pharm Sin B 2012;2:60–9.
5. Giebisch G. The use of diuretic agent as a probe to investigate site
and mechanism of ion transport process. Arzneimittelforschung
1985;35:336–42.
6. Giancarlo S, Inventor. Controlled-release mucoadhesive pharma-
ceutical composition for the oral administration of furosemide.
US Patent 5571533; 1996 November 5.
7. Ozdemir N, Ordu S, Ozkan Y. Studies on ﬂoating dosage forms of
furosemide: in vitro and in vivo evaluations of bilayer tablet
formulations. Drug Dev Ind Pharm 2000;26:857–66.
8. Shidhaye SS, Saindane NS, Sutar S, Kadam V. Mucoadhesive
bilayered patches for administration of sumatriptan succunate.
AAPS PharmSciTech 2008;9:909–16.
9. Noha AN. Design and characterization of mucoadhesive buccal
patches containing cetylpyridinium chloride. Acta Pharm
2003;53:199–212.
10. Perioli L, Ambrogi V, Angelici F, Ricci M, Giovagnoli S, Capuccell
M, et al. Development of mucoadhesive patches for buccal admin-
istration of ibuprofen. J Control Release 2004;99:73–82.
11. Kok KP, Choy FW. Polymeric ﬁlms as vehicle for buccal delivery:
swelling, mechanical, and mucoadhesive properties. J Pharm
Pharm Sci 1999;2:53–61.
12. Dixit RP, Puthli SP. Oral strip technology: overview and future
potential. J Control Release 2009;139:94–7.
13. Baveja SK, KVR Rao, Devi KP. Zero-order release hydrophilic
matrix tablets of b-adrenergic blockers. Int J Pharm 1987;39:
39–45.
14. Pitha J, Inventor. Pharmaceutical preparations containing cyclo-
dextrin derivatives. US Patent 4727064; 1988 February 23.
15. Lajos S, Jozsef S. Highly soluble cyclodextrin derivatives: chem-
istry, properties, and trends in development. Adv Drug Deliv Rev
1999;36:17–28.
16. Agarwal V, Mishra B. Design, development, and biopharmaceu-
tical properties of buccoadhesive compacts of pentazocine. Drug
Dev Ind Pharm 1999;25:701–9.
17. Gu JM, Robinson JR, Leung SH. Binding of acrylic polymers to
mucin/epithelial surface: structure-property relationships. Crit Rev
Ther Drug Carrier Syst 1988;5:21–67.
18. Choi MK, Jung JH, Ryu JM, Yoon SJ, Oh YK, Kim CK.
Development of in-situ gelling and mucoadhesive acetaminophen
liquid suppository. Int J Pharm 1998;165:33–44.
19. Singla AK, Chawla M, Singh A. Potential applications of
carbomer in oral mucoadhesive controlled drug delivery system:
a review. Drug Dev Ind Pharm 2000;26:913–24.
20. Dash V, Mishra SK, Singh M, Goyal AK, Rath G. Release kinetic
studies of aspirin microcapsules from ethyl cellulose, cellulose
acetate phthalate and their mixtures by emulsion solvent evapora-
tion method. Sci Pharm 2010;78:93–101.
